JAMA Network Open
EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, JANUARY 5, 2021
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.33706?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=010521
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
What The Study Did: Data from public health surveillance of reported COVID-19 cases and seroprevalence surveys were used in this observational study that reports an estimated 46.9 million SARS-CoV-2 infections, 28.1 million symptomatic infections, 956,174 hospitalizations and 304,915 deaths occurred in the U.S. through November 15, 2020.
Authors: Frederick J. Angulo, D.V.M., Ph.D., of Medical Development and Scientific/Clinical Affairs of Pfizer Vaccines, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.